In a significant shift reflecting intensifying pressure to control escalating healthcare expenditures, a growing number of U.S. employers are beginning to discontinue coverage for GLP-1 medications primarily prescribed for weight loss. This move is part of a broader strategy that includes exploring nontraditional benefit plans and implementing various cost-curbing measures as healthcare costs continue their relentless ascent. A recent survey conducted by Mercer in April and May 2026 underscores this trend, revealing a challenging landscape for organizations grappling with the financial implications of employee health benefits.
The Mercer survey, which polled 604 U.S. organizations, including 408 large employers with 500 or more employees and 123 smaller firms, found that 6% of large employers had already dropped coverage for weight-loss-related GLP-1s in 2026. An additional 5% are actively considering or planning to eliminate this coverage in the coming year, signaling a more widespread reevaluation of these increasingly popular but expensive drugs. This marks a notable change from the previous year when approximately half of large employers offered such coverage.
The Rise and Cost of GLP-1 Medications
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking class of drugs that have revolutionized the treatment of type 2 diabetes and, more recently, chronic weight management. Medications like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) work by mimicking a natural hormone that helps regulate blood sugar and appetite. Their effectiveness in promoting significant weight loss—often 15-20% of body weight or more—has led to unprecedented demand, transforming the pharmaceutical market and offering new hope to millions struggling with obesity.
The journey of GLP-1 agonists began with their approval for type 2 diabetes, with drugs like liraglutide (Victoza) and semaglutide (Ozempic) showing remarkable efficacy in blood sugar control and cardiovascular benefits. The turning point for weight loss came with the FDA approval of Wegovy in June 2021 specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. This was followed by Zepbound’s approval in November 2023, which offered even greater weight loss potential. The rapid uptake of these drugs, driven by widespread media attention and patient demand, quickly exposed the immense financial strain they could place on healthcare systems and employer-sponsored plans.
The high cost of GLP-1 medications is a primary concern for employers. Monthly out-of-pocket costs for these drugs can range from $900 to over $1,300 without insurance, translating to annual expenses that can exceed $15,000 per patient. When considering the millions of Americans eligible for these medications, the aggregate cost for employers could run into billions of dollars, creating an unsustainable trajectory for benefit budgets. This financial burden is compounded by the fact that these medications are often required long-term to maintain their effects, making the cost a perpetual drain rather than a one-time investment.
Escalating Healthcare Costs: A Broader Picture
The decision to scale back GLP-1 coverage is not an isolated phenomenon but rather a symptom of a larger, systemic issue: the relentless rise of healthcare costs across the United States. According to Mercer, prescription drug benefits are a significant contributor to these rising costs, with drug expenses increasing by an average of 9% in 2026 alone. This increase outpaces general inflation and other components of healthcare spending, making pharmaceutical benefits a key target for cost containment.
Beyond prescription drugs, several other factors contribute to the overall escalation of healthcare expenditures:
- Aging Population: The demographic shift towards an older population means a greater prevalence of chronic diseases and a higher demand for medical services, driving up utilization and costs.
- Chronic Diseases: Conditions like heart disease, cancer, diabetes, and respiratory illnesses account for a substantial portion of healthcare spending, requiring ongoing and often expensive treatments.
- Advancements in Medical Technology: While beneficial, new diagnostic tools, surgical techniques, and treatments often come with hefty price tags, increasing the overall cost of care.
- Hospital and Provider Consolidation: Mergers and acquisitions among hospitals and healthcare systems can reduce competition, leading to higher prices for services.
- Administrative Overhead: The complex U.S. healthcare system is characterized by significant administrative costs associated with billing, insurance processing, and regulatory compliance.
- Lifestyle Factors: Rising rates of obesity and sedentary lifestyles contribute to the incidence of chronic conditions, further straining healthcare resources.
These interwoven factors create a complex environment where employers are constantly battling against rising premiums and benefit expenses, directly impacting their bottom line and their ability to offer competitive compensation packages.
The Precarious Position of American Workers
The current economic climate exacerbates the challenge for employers. Workers in the U.S. are already grappling with the stresses of a low-hire labor market, creating job insecurity and limiting opportunities for advancement. The looming specter of artificial intelligence and its potential negative impacts on employment adds another layer of anxiety. Furthermore, persistent high inflation continues to erode purchasing power, making every dollar count more than ever.
In this context, transferring additional healthcare costs onto employees is a precarious move. While a June survey by the Coalition to Strengthen America’s Healthcare indicated that Americans primarily blame insurers, the federal government, and drug companies for rising costs rather than their employers, companies remain sensitive to the financial strain their workforce is under. Simon Camaj, U.S. health leader at Mercer, articulated this delicate balance: “Employers are under intense pressure to manage another year of elevated health benefit cost growth, but they also know that affordability matters deeply to employees.”
Shifting higher costs to employees can have far-reaching consequences beyond diminished morale. Studies consistently show that when out-of-pocket expenses become prohibitive, employees are more likely to reduce or delay necessary medical care. This deferral of treatment for conditions—whether chronic or acute—can lead to worsening health outcomes, more complex and expensive interventions down the line, and increased absenteeism or reduced productivity in the workplace. What begins as a cost-saving measure can thus paradoxically increase overall healthcare costs for both employees and employers in the long term, creating a vicious cycle.
Exploring Nontraditional Plans and Other Strategies
To mitigate the escalating costs, employers are actively exploring a range of strategies beyond simply cutting GLP-1 coverage. These approaches often aim to improve efficiency, promote preventive care, and offer more cost-effective access to services. Some of the nontraditional plans and strategies include:
- Self-Insurance: Many large employers self-insure their health plans, meaning they directly bear the risk of medical claims rather than paying a fixed premium to an insurance carrier. This allows for greater control over plan design, data analysis, and vendor selection, potentially leading to significant savings.
- Reference-Based Pricing: Instead of negotiating rates with providers, employers establish a maximum payment amount for specific services (e.g., knee surgery, MRI scans). If a provider charges more, the employee is responsible for the difference, encouraging them to seek more cost-effective options.
- Direct Primary Care (DPC): DPC models involve a monthly membership fee paid directly to a primary care physician, offering enhanced access, longer appointments, and often including basic lab tests and procedures, thereby reducing reliance on fee-for-service models.
- Enhanced Wellness Programs: Investing in comprehensive wellness initiatives that focus on chronic disease management, mental health, nutrition, and physical activity can improve employee health and reduce the need for costly interventions in the future.
- Telehealth Expansion: Expanding access to virtual care for routine consultations, mental health services, and chronic condition management can offer convenience and cost savings by reducing emergency room visits and in-person specialist appointments.
- High-Deductible Health Plans (HDHPs) with Health Savings Accounts (HSAs): These plans encourage consumer-driven healthcare by giving employees more control over their spending while offering tax-advantaged savings for medical expenses.
- Narrow Networks: Employers may partner with specific networks of providers that offer services at discounted rates in exchange for a higher volume of patients.
- Formulary Management and Prior Authorization: Stricter management of prescription drug formularies and implementing prior authorization requirements for high-cost medications can help control pharmaceutical spending.
- Centers of Excellence Programs: For complex or high-cost procedures, employers may direct employees to specific hospitals or clinics renowned for quality and cost-efficiency in those areas.
These strategies reflect a growing sophistication in how employers approach benefits management, moving beyond traditional insurance models to more proactive and data-driven approaches.
Implications and the Road Ahead
The ongoing reevaluation of GLP-1 coverage and the broader push for cost containment carry significant implications for various stakeholders:
- For Employers: The balancing act between managing escalating costs and maintaining competitive, attractive benefits for talent acquisition and retention is becoming increasingly complex. Employers must weigh the financial savings against potential negative impacts on employee morale, health outcomes, and productivity.
- For Employees: Access to potentially life-changing medications like GLP-1s could become a lottery, dependent on their employer’s benefit decisions. This could lead to health disparities and financial burdens for those who need these drugs but lose coverage. It also reinforces the idea that healthcare access remains a significant source of stress and insecurity.
- For the Pharmaceutical Industry: The decisions by employers could put downward pressure on drug pricing, especially for new and expensive medications. It might also encourage pharmaceutical companies to explore value-based contracting or alternative pricing models to ensure broader access.
- For the Healthcare System: The trend highlights the systemic challenges within U.S. healthcare, prompting further discussions on pricing transparency, cost-effectiveness, and the equitable distribution of advanced medical treatments.
Looking ahead, the landscape of employer-sponsored health benefits is expected to remain highly dynamic. The rapid pace of medical innovation, coupled with persistent inflationary pressures and a competitive labor market, will continue to force employers to adapt. While the immediate focus is on managing the costs associated with GLP-1s and other high-expense areas, the long-term trend points toward a more holistic approach to employee well-being, where preventive care, mental health support, and efficient care delivery models play an increasingly central role. The goal remains to provide valuable benefits without bankrupting the organization, a challenge that will require ongoing innovation, careful analysis, and a deep understanding of both financial realities and employee needs.
